- Global Pharma News & Resources

Destiny Pharma to present at the 2019 Gordon Research Conference

Brighton, United Kingdom – 31 July 2019 – Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development of novel anti-microbial drugs which address the global problem of anti-microbial resistance (AMR), announces that Dr Jesus Gonzalez, Chief Medical Officer of Destiny Pharma, has been invited to present on the clinical potential of the Company’s lead asset, XF-73, in the prevention of post-operative Staphylococcal infections at the prestigious Gordon Research Conference (GRC), on staphylococcal diseases, on 4-9 August, 2019 in Castelldefels, Spain.

XF-73 is the Company's lead candidate for the prevention of post-surgical staphylococcal infections. It is currently in Phase 2b clinical development as a nasal gel formulation to eradicate the bacteria Staphylococcus aureus, including Methicillin-resistant Staphylococcus aureus (MRSA), that are a common cause of potentially lethal post-surgical infections.

About Gordon Research Conference

The first GRC took place at Johns Hopkins University, Baltimore in 1931. The meeting was convened by Professor Neil E. Gordon, who's interest was to bring together a group of scientists working at the frontier of research of a particular area to discuss, in depth, all aspects of the most recent advances in the field and to stimulate new directions for research. GRC continues this tradition of fostering scientific communities that focus on the latest, unpublished research at the frontiers of the field. GRC now holds more than 100 meetings each year in the USA, Italy, Switzerland, Spain and Hong Kong.

About Destiny Pharma

Destiny Pharma is an established, clinical stage, innovative biotechnology company focused on the development of novel medicines that represent a new approach to the treatment of infectious disease. These potential new medicines are being developed to address the need for new drugs for the prevention and treatment of life-threatening infections caused by antibiotic-resistant bacteria, often referred to as “superbugs”. Tackling anti-microbial resistance has become a global imperative recognised by the World Health Organisation (WHO) and the United Nations, as well as the G7 and the G20 countries. For further information, please visit

About XF-73

XF-73 is a synthetic anti-microbial active against all tested Staphylococcus aureus strains, including drug resistant strains. By acting via a cell-surface mechanism it affects the bacterial membrane permeability and integrity, leading to cell death. XF-73 has already been through five successful Phase I/IIb clinical trials showing rapid antibacterial action. In standard microbiology studies XF drugs have demonstrated a unique no/low resistance profile that means that XF compounds have the potential to deliver novel drugs that are clearly differentiated from traditional antibiotics where resistance limits their utility.

XF-73 is being studies for the prevention of post-surgical staphylococcal infections. In the US, there are approximately 40 million surgeries per annum alone where the patient is at risk of a post-surgical infection. However, within this large population there are particular groups who are at an even higher risk of infection due to the nature of their surgery or the procedures and/or their specific hospital environment in which they are treated. These higher risk surgical procedures include cardiovascular, orthopaedic and other complex surgeries. Destiny Pharma estimates that this totals approximately 14 million US surgeries per year, with this figure set to rise within the context of an ageing population.

Editor Details

  • Company:
    • Destiny Pharma
  • Name:
    • Destiny Pharma
Last Updated: 31-Jul-2019